Balincourt, C. de

patient sarcoma group treatment response cycle grade cancer study non-gist group tissue tissue sarcoma progression non-gist gist group agent toxicity trial month brostallicin grade 3 tumour phase therapy european criteria table activity disease design response rate end-point cancer 4 3 fi rst step journal event 10 mg /m bone sarcoma group survival dose reduction verweij j range eortc eortc stbsg month progression firmed neutropenia doxorubicin assessment chemotherapy evaluable tissue sarcomas histotype tumour progression unclassi fied sarcoma objective fi brous histiocytoma phase ii study phase i study judson i reaction metastatic ctc grade research ficacy ef ficacy glutathione ifosfamide stbsg stromal serum groove reduction granulocytopenia binder verweij thrombocytopenia imatinib pharmacia disagreement